Travere Therapeutics, Inc.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for people living with rare kidney and metabolic diseases in the United States. Its commercial products include FILSPARI (sparsentan), a once-daily oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II), and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic disorder that causes high cystine levels in the urine and recurring kidney stones. The company also has clinical-stage programs, including Sparsentan for focal segmental glomerulosclerosis and Pegtibatinase for classical homocystinuria.

Travere Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol TVTX. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, its shares are traded in the United States, and investors typically use USD to buy and sell its stock.

Travere Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing and delivering therapies for rare kidney and metabolic diseases. Biotechnology companies like Travere use biological processes and research to create drugs and treatments, often targeting conditions with limited existing options.

Travere Therapeutics is headquartered in San Diego, California, United States. The company primarily serves the US market, as indicated by its description summary, which states it delivers therapies to people living with rare kidney and metabolic diseases in the United States. Its operations and commercial activities are centered in the US, though it may collaborate internationally, such as with PharmaKrysto Limited for pre-clinical activities related to cystinuria.

Travere Therapeutics' main commercial products are FILSPARI (sparsentan) for IgA Nephropathy, and Thiola and Thiola EC (tiopronin tablets) for cystinuria. Its clinical-stage pipeline includes Sparsentan, which has Orphan Drug Designation for focal segmental glomerulosclerosis in the US and Europe, and Pegtibatinase, a novel investigational human enzyme replacement candidate for classical homocystinuria. The company also has a collaboration with PharmaKrysto Limited for pre-clinical activities in the cystinuria program.